RedHill Biopharma (RDHL) Other Non-Current Assets (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Other Non-Current Assets data on file, last reported at $169000.0 in Q4 2025.

• Other Non-Current Assets for Q4 2025 came in at $169000.0, up 14.19% year-over-year; the trailing twelve-month figure through Dec 2025 was $169000.0 (up 14.19% YoY), and the FY2025 annual result was $169000.0, up 14.19% from the prior year.
• Other Non-Current Assets climbed to $169000.0 in Q4 2025 per RDHL's latest filing, from $160000.0 in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $16.2 million in Q4 2021 and troughed at $148000.0 in Q4 2024.
• A 5-year average of $10.1 million and a median of $16.0 million in 2022 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets plunged 95.06% in 2023, then gained 14.19% in 2025.
• A 5-year view of Other Non-Current Assets shows it stood at $16.2 million in 2021, then declined by 1.05% to $16.0 million in 2022, then sank by 95.06% to $790000.0 in 2023, then tumbled by 81.27% to $148000.0 in 2024, then grew by 14.19% to $169000.0 in 2025.
• Business Quant data shows RDHL's Other Non-Current Assets at $169000.0 in Q4 2025, $160000.0 in Q2 2025, and $148000.0 in Q4 2024.